Does the media favor PTGX or VRDN?

In the previous week, Viridian Therapeutics had 3 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 5 mentions for Viridian Therapeutics and 2 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 0.83 beat Viridian Therapeutics' score of 0.64 indicating that Protagonist Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protagonist Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Viridian Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer IBRX or VRDN?

In the previous week, ImmunityBio had 3 more articles in the media than Viridian Therapeutics. MarketBeat recorded 8 mentions for ImmunityBio and 5 mentions for Viridian Therapeutics. ImmunityBio's average media sentiment score of 0.67 beat Viridian Therapeutics' score of 0.64 indicating that ImmunityBio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmunityBio 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Viridian Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to VRDN or TGTX?

In the previous week, Viridian Therapeutics had 1 more articles in the media than TG Therapeutics. MarketBeat recorded 5 mentions for Viridian Therapeutics and 4 mentions for TG Therapeutics. Viridian Therapeutics' average media sentiment score of 0.64 beat TG Therapeutics' score of 0.26 indicating that Viridian Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viridian Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TG Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer PCVX or VRDN?

In the previous week, Viridian Therapeutics had 3 more articles in the media than Vaxcyte. MarketBeat recorded 5 mentions for Viridian Therapeutics and 2 mentions for Vaxcyte. Viridian Therapeutics' average media sentiment score of 0.64 beat Vaxcyte's score of 0.33 indicating that Viridian Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vaxcyte 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Viridian Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Viridian Therapeutics (VRDN) Competitors

$19.40 +0.41 (+2.16%)

Closing price 04:00 PM Eastern

Extended Trading

$19.46 +0.07 (+0.34%)

As of 07:35 PM Eastern

Compare

VRDN vs. PTGX, IBRX, TGTX, APGE, and PCVX

Should you buy Viridian Therapeutics stock or one of its competitors? Viridian Therapeutics's main competitors and comparable companies include Protagonist Therapeutics (PTGX), ImmunityBio (IBRX), TG Therapeutics (TGTX), Apogee Therapeutics (APGE), and Vaxcyte (PCVX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Viridian Therapeutics compare to Protagonist Therapeutics?

Protagonist Therapeutics (NASDAQ:PTGX) and Viridian Therapeutics (NASDAQ:VRDN) are both mid-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, risk, analyst recommendations, valuation, institutional ownership, profitability and media sentiment.

Protagonist Therapeutics has a beta of 1.53, indicating that its stock price is 53% more volatile than the broader market. Comparatively, Viridian Therapeutics has a beta of 1.11, indicating that its stock price is 11% more volatile than the broader market.

98.6% of Protagonist Therapeutics shares are held by institutional investors. 5.2% of Protagonist Therapeutics shares are held by company insiders. Comparatively, 2.4% of Viridian Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Protagonist Therapeutics has higher earnings, but lower revenue than Viridian Therapeutics. Viridian Therapeutics is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$46.02M	196.87	-$130.15M	$1.03	135.93
Viridian Therapeutics	$70.85M	31.05	-$342.60M	-$3.37	N/A

Protagonist Therapeutics has a net margin of 29.40% compared to Viridian Therapeutics' net margin of -505.86%. Protagonist Therapeutics' return on equity of 12.03% beat Viridian Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	29.40%	12.03%	11.23%
Viridian Therapeutics	-505.86%	-72.97%	-42.80%

Protagonist Therapeutics presently has a consensus price target of $147.13, suggesting a potential upside of 5.09%. Viridian Therapeutics has a consensus price target of $38.69, suggesting a potential upside of 99.24%. Given Viridian Therapeutics' higher possible upside, analysts clearly believe Viridian Therapeutics is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	0 Sell rating(s)	2 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.89
Viridian Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85

In the previous week, Viridian Therapeutics had 3 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 5 mentions for Viridian Therapeutics and 2 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 0.83 beat Viridian Therapeutics' score of 0.64 indicating that Protagonist Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protagonist Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Viridian Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Protagonist Therapeutics beats Viridian Therapeutics on 13 of the 16 factors compared between the two stocks.

How does Viridian Therapeutics compare to ImmunityBio?

ImmunityBio (NASDAQ:IBRX) and Viridian Therapeutics (NASDAQ:VRDN) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk, media sentiment and institutional ownership.

ImmunityBio presently has a consensus price target of $14.20, indicating a potential upside of 38.17%. Viridian Therapeutics has a consensus price target of $38.69, indicating a potential upside of 99.24%. Given Viridian Therapeutics' higher possible upside, analysts clearly believe Viridian Therapeutics is more favorable than ImmunityBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Viridian Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85

Viridian Therapeutics has a net margin of -505.86% compared to ImmunityBio's net margin of -598.55%. ImmunityBio's return on equity of 0.00% beat Viridian Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-598.55%	N/A	-51.65%
Viridian Therapeutics	-505.86%	-72.97%	-42.80%

In the previous week, ImmunityBio had 3 more articles in the media than Viridian Therapeutics. MarketBeat recorded 8 mentions for ImmunityBio and 5 mentions for Viridian Therapeutics. ImmunityBio's average media sentiment score of 0.67 beat Viridian Therapeutics' score of 0.64 indicating that ImmunityBio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmunityBio	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Viridian Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

8.6% of ImmunityBio shares are held by institutional investors. 66.1% of ImmunityBio shares are held by insiders. Comparatively, 2.4% of Viridian Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Viridian Therapeutics has lower revenue, but higher earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Viridian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	$113.29M	96.14	-$351.40M	-$0.97	N/A
Viridian Therapeutics	$70.85M	31.05	-$342.60M	-$3.37	N/A

ImmunityBio has a beta of 0.02, meaning that its share price is 98% less volatile than the broader market. Comparatively, Viridian Therapeutics has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market.

Summary

ImmunityBio beats Viridian Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Viridian Therapeutics compare to TG Therapeutics?

Viridian Therapeutics (NASDAQ:VRDN) and TG Therapeutics (NASDAQ:TGTX) are both mid-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability, media sentiment and analyst recommendations.

Viridian Therapeutics presently has a consensus target price of $38.69, indicating a potential upside of 99.24%. TG Therapeutics has a consensus target price of $63.00, indicating a potential upside of 15.94%. Given Viridian Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Viridian Therapeutics is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viridian Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
TG Therapeutics	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.44

Viridian Therapeutics has a beta of 1.11, indicating that its share price is 11% more volatile than the broader market. Comparatively, TG Therapeutics has a beta of 1.8, indicating that its share price is 80% more volatile than the broader market.

58.6% of TG Therapeutics shares are owned by institutional investors. 2.4% of Viridian Therapeutics shares are owned by insiders. Comparatively, 8.9% of TG Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

TG Therapeutics has higher revenue and earnings than Viridian Therapeutics. Viridian Therapeutics is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viridian Therapeutics	$70.85M	31.05	-$342.60M	-$3.37	N/A
TG Therapeutics	$616.29M	13.50	$447.18M	$2.74	19.83

TG Therapeutics has a net margin of 55.22% compared to Viridian Therapeutics' net margin of -505.86%. TG Therapeutics' return on equity of 73.49% beat Viridian Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viridian Therapeutics	-505.86%	-72.97%	-42.80%
TG Therapeutics	55.22%	73.49%	34.14%

In the previous week, Viridian Therapeutics had 1 more articles in the media than TG Therapeutics. MarketBeat recorded 5 mentions for Viridian Therapeutics and 4 mentions for TG Therapeutics. Viridian Therapeutics' average media sentiment score of 0.64 beat TG Therapeutics' score of 0.26 indicating that Viridian Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viridian Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TG Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

TG Therapeutics beats Viridian Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Viridian Therapeutics compare to Apogee Therapeutics?

Apogee Therapeutics (NASDAQ:APGE) and Viridian Therapeutics (NASDAQ:VRDN) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, media sentiment, dividends, earnings and risk.

Apogee Therapeutics has a net margin of 0.00% compared to Viridian Therapeutics' net margin of -505.86%. Apogee Therapeutics' return on equity of -29.88% beat Viridian Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apogee Therapeutics	N/A	-29.88%	-28.08%
Viridian Therapeutics	-505.86%	-72.97%	-42.80%

Apogee Therapeutics has higher earnings, but lower revenue than Viridian Therapeutics. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Viridian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.34	N/A
Viridian Therapeutics	$70.85M	31.05	-$342.60M	-$3.37	N/A

Apogee Therapeutics has a beta of 0.33, indicating that its share price is 67% less volatile than the broader market. Comparatively, Viridian Therapeutics has a beta of 1.11, indicating that its share price is 11% more volatile than the broader market.

79.0% of Apogee Therapeutics shares are owned by institutional investors. 24.3% of Apogee Therapeutics shares are owned by insiders. Comparatively, 2.4% of Viridian Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Apogee Therapeutics currently has a consensus price target of $126.77, suggesting a potential downside of 6.14%. Viridian Therapeutics has a consensus price target of $38.69, suggesting a potential upside of 99.24%. Given Viridian Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Viridian Therapeutics is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apogee Therapeutics	1 Sell rating(s)	15 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.16
Viridian Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85

In the previous week, Viridian Therapeutics had 5 more articles in the media than Apogee Therapeutics. MarketBeat recorded 5 mentions for Viridian Therapeutics and 0 mentions for Apogee Therapeutics. Viridian Therapeutics' average media sentiment score of 0.64 beat Apogee Therapeutics' score of 0.00 indicating that Viridian Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Apogee Therapeutics	Neutral
Viridian Therapeutics	Positive

Summary

Viridian Therapeutics beats Apogee Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Viridian Therapeutics compare to Vaxcyte?

Vaxcyte (NASDAQ:PCVX) and Viridian Therapeutics (NASDAQ:VRDN) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, profitability, dividends, valuation, analyst recommendations, earnings and media sentiment.

Vaxcyte currently has a consensus target price of $104.40, indicating a potential upside of 84.15%. Viridian Therapeutics has a consensus target price of $38.69, indicating a potential upside of 99.24%. Given Viridian Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Viridian Therapeutics is more favorable than Vaxcyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Viridian Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85

Vaxcyte has a beta of 1.23, meaning that its share price is 23% more volatile than the broader market. Comparatively, Viridian Therapeutics has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market.

In the previous week, Viridian Therapeutics had 3 more articles in the media than Vaxcyte. MarketBeat recorded 5 mentions for Viridian Therapeutics and 2 mentions for Vaxcyte. Viridian Therapeutics' average media sentiment score of 0.64 beat Vaxcyte's score of 0.33 indicating that Viridian Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vaxcyte	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Viridian Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Viridian Therapeutics has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Viridian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxcyte	N/A	N/A	-$766.63M	-$7.63	N/A
Viridian Therapeutics	$70.85M	31.05	-$342.60M	-$3.37	N/A

Vaxcyte has a net margin of 0.00% compared to Viridian Therapeutics' net margin of -505.86%. Vaxcyte's return on equity of -37.56% beat Viridian Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxcyte	N/A	-37.56%	-33.62%
Viridian Therapeutics	-505.86%	-72.97%	-42.80%

96.8% of Vaxcyte shares are owned by institutional investors. 3.3% of Vaxcyte shares are owned by insiders. Comparatively, 2.4% of Viridian Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Viridian Therapeutics beats Vaxcyte on 9 of the 15 factors compared between the two stocks.

Get Viridian Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRDN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VRDN vs. The Competition

Export

Metric	Viridian Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.20B	$3.84B	$7.10B	$13.24B
Dividend Yield	N/A	3.64%	2.53%	15.88%
P/E Ratio	-5.76	12.99	274.61	26.05
Price / Sales	31.02	1,288.54	601.02	89.39
Price / Cash	N/A	121.76	77.38	51.25
Price / Book	3.14	16.63	10.92	6.31
Net Income	-$342.60M	-$22.67M	$3.50B	$361.43M
7 Day Performance	-5.23%	-3.06%	-2.11%	-1.67%
1 Month Performance	-14.84%	-10.76%	-6.34%	-3.94%
1 Year Performance	-8.58%	21.10%	8.81%	2.77%

Viridian Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VRDN Viridian Therapeutics	2.7794 of 5 stars	$19.40 +2.2%	$38.69 +99.4%	-10.7%	$2.20B	$70.85M	N/A	252
PTGX Protagonist Therapeutics	1.6418 of 5 stars	$142.44 +0.4%	$147.13 +3.3%	+117.5%	$9.18B	$46.02M	138.29	141	News Coverage Insider Trade
IBRX ImmunityBio	2.8331 of 5 stars	$8.51 +0.8%	$14.20 +66.9%	+274.2%	$8.95B	$113.29M	N/A	691
TGTX TG Therapeutics	3.372 of 5 stars	$56.19 -2.2%	$63.00 +12.1%	+46.7%	$8.79B	$616.29M	20.51	399
APGE Apogee Therapeutics	0.8275 of 5 stars	$135.07 flat	$126.77 -6.1%	N/A	$8.40B	N/A	N/A	91

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VRDN) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Viridian Therapeutics (VRDN) Competitors

VRDN vs. PTGX, IBRX, TGTX, APGE, and PCVX

How does Viridian Therapeutics compare to Protagonist Therapeutics?

Summary

How does Viridian Therapeutics compare to ImmunityBio?

Summary

How does Viridian Therapeutics compare to TG Therapeutics?

Summary

How does Viridian Therapeutics compare to Apogee Therapeutics?

Summary

How does Viridian Therapeutics compare to Vaxcyte?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRDN vs. The Competition

Viridian Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Viridian Therapeutics (VRDN) Competitors

VRDN vs. PTGX, IBRX, TGTX, APGE, and PCVX

How does Viridian Therapeutics compare to Protagonist Therapeutics?

Which has more volatility and risk, PTGX or VRDN?

Do insiders and institutionals hold more shares of PTGX or VRDN?

Which has better valuation & earnings, PTGX or VRDN?

Is PTGX or VRDN more profitable?

Do analysts prefer PTGX or VRDN?

Does the media favor PTGX or VRDN?

Summary

How does Viridian Therapeutics compare to ImmunityBio?

Do analysts prefer IBRX or VRDN?

Is IBRX or VRDN more profitable?

Does the media prefer IBRX or VRDN?

Do insiders & institutionals have more ownership in IBRX or VRDN?

Which has stronger earnings and valuation, IBRX or VRDN?

Which has more volatility & risk, IBRX or VRDN?

Summary

How does Viridian Therapeutics compare to TG Therapeutics?

Do analysts prefer VRDN or TGTX?

Which has more risk and volatility, VRDN or TGTX?

Do insiders and institutionals believe in VRDN or TGTX?

Which has stronger earnings and valuation, VRDN or TGTX?

Is VRDN or TGTX more profitable?

Does the media refer more to VRDN or TGTX?

Summary

How does Viridian Therapeutics compare to Apogee Therapeutics?

Is APGE or VRDN more profitable?

Which has higher earnings & valuation, APGE or VRDN?

Which has more risk and volatility, APGE or VRDN?

Do institutionals and insiders hold more shares of APGE or VRDN?

Do analysts recommend APGE or VRDN?

Does the media favor APGE or VRDN?

Summary

How does Viridian Therapeutics compare to Vaxcyte?

Do analysts prefer PCVX or VRDN?

Which has more risk and volatility, PCVX or VRDN?

Does the media prefer PCVX or VRDN?

Which has preferable earnings & valuation, PCVX or VRDN?

Is PCVX or VRDN more profitable?

Do institutionals and insiders believe in PCVX or VRDN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRDN vs. The Competition

Viridian Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools